No Cracks In Antitrust Suit Against Biogen, Rival Argues

By Eric Kroh (August 14, 2017, 2:19 PM EDT) -- Ixchel Pharma LLC on Friday told a California federal court it had already suffered financial losses due to rival Biogen Inc.'s alleged anti-competitive scheme to undermine its development of a treatment for a rare neuromuscular disease and asked that its lawsuit be allowed to proceed.

It is no mere speculation that Biogen harmed Ixchel by buying off its collaborator Forward Pharma FA ApS, with whom it was working on a drug to treat Friedreich's ataxia, Ixchel said in a response to Biogen's bid to dismiss the case.

"Ixchel is a direct victim of Biogen's anti-competitive conduct, and therefore stands as the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Subscribers Only

Nature of Suit

Subscribers Only


Subscribers Only

Date Filed

Subscribers Only

Law Firms


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!